Binnur ÖNAL, Ahmet ŞAHPAZ, Ahmet YEŞİLYURT, Tuncay DELİBAŞI, Ünsal HAN

Brafv600e mutation, ret/ptc1 and pax8-ppar gamma rearrangements in follicular epithelium derived thyroid lesions-institutional experience and literature review

Background: Thyroid cancers are the most frequentlyoccurring endocrine malignancy worldwide. In Turkey,thyroid cancers are ranked 2nd on the incidence list inwomen, with a rate of 16.2%, but they are not includedamong the top 10 cancer types in men. Aims: To identify the contribution of the BRAFV600E mutation, and the RET/PTC1 and PAX8-PPARγ rear - rangements in the diagnosis and differential diagnosisof follicular epithelial-derived thyroid lesions. Study Design: Retrospective clinical and moleculargenetic study. Methods: A total of 86 thyroid cases diagnosed be- tween 2001 and 2012 at the Department of Pathologywere included in the retrospective study group. Sam- ples best representing the lesion and comprising cap- sules were chosen in the selection of paraffin blockspertaining to the cases. The BRAFV600E mutation, andthe RET/PTC1 and PAX8-PPARγ rearrangements wereinvestigated in all cases. Results: The BRAFV600E mutation was observed in 12out of 37 papillary carcinoma cases (32.4%), in 1 outof 15 follicular carcinoma cases (6.6%), and in 1 out of7 undifferentiated carcinoma cases (14.3%). No muta- tion was detected in benign lesions. The RET/PTC1 rearrangement was detected in 2 out of 7 undifferentiated carcinoma cases (28.6%), and in1 out of 15 follicular carcinoma cases (6.6%). No generearrangement was detected in benign lesions.The PAX8-PPARγ rearrangement was detected in 5 outof 15 follicular thyroid carcinoma cases (33.3%) and in1 out of 15 follicular adenoma cases (6.6%).Conclusion: The BRAFV600E mutation and RET/PTC1rearrangement were effective in distinguishing the fol-licular epithelium-derived benign and malignant lesionsof the thyroid in the resection materials. The BRAFV600Emutation was rather specific to papillary carcinoma inthe thyroid, and in cases where the BRAFV600E mutationwas detected, multi-centricity, lymph node metastasisand capsular invasion findings were observed morefrequently compared to cases in which no mutationwas observed. The PAX8-PPARγ rearrangement wasobserved to be more effective in the differentiation ofadenomas and carcinomas in follicular neoplasms ofthe thyroid, whereas the RET/PTC1 analysis contrib-uted to the differential diagnosis of papillary carcinomahistogenesis at a frequency of 29% in undifferentiatedthyroid carcinomas.

PDF

___

1. Public Healthy Institution of Turkey; Cancer Department; Turk- ish cancer incidence; 2009 http://kanser.gov.tr/daire-faaliyetleri/ kanser-istatistikleri/922-2009-kanser-insidansları.html.
2. Salvatore G, Giannini R, Faviana P, Caleo A, Migliaccio I, Fagin JA, et al. Analysis of BRAF point mutation and RET/ PTC rearrangement refines the fine-needle aspiration diagno- sis of papillary thyroid carcinoma. J Clin Endocrinol Metab 2004;89:5175-80. [CrossRef]
3. Kocjan G, Feichter G, Hagmar B, Kapila K, I.Kardum-Skelin, Kloboves-Prevodnik V, et al. Fine needle aspiration cytology: a survey of current European practice. Cytopathology 2006; 17:219-26. [CrossRef]
4. Ali SZ. Thyroid cytopathology: Bethesda and beyond. Acta Cy- tol 2011;55:4-12. [CrossRef]
5. Tubbs RR, Stoler MH. Molecular Endocrine Pathology in Gold- blum JR (eds), Cell and tissue based molecular pathology. Else- vier 2009; 296-300.
6. Zhu Z, Gandhi M, Nikiforova MN, Fischer AH, Nikiforov YE. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma, an unusu- ally high prevalence of RAS mutations. Am J Clin Pathol 2003;120:71-7. [CrossRef]
7. Nikiforov YE, Ohori NP, Hodak SP, Carty SE, LeBeau SO, Fer- ris RL, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thy- roid nodules: A prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab 2011;96:3390-7. [CrossRef]
8. Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z, et al. Molecular testing for mutations in im- proving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 2009;94:2092-8. [CrossRef]
9. Giordano TJ, Kuick R, Thomas DG, Misek DE, Vinco M, Sand- ers D, et al. Molecular classification of papillary thyroid car- cinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analy- sis. Oncogene 2005;24:6646-56. [CrossRef]
10. Pizzolanti G, Russo L, Richiusa P, Bronte V, Nuara RB, Rodolico V, et al. Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement. Thyroid 2007;17:1109-15. [CrossRef]
11. Cheung CC, Ezzat S, Ramyar L, Freeman JL, Asa SL. Molecular basis of hurtle cell papillary thyroid. J Clin Endocrinol Metab 2000;85:878-82. [CrossRef]
12. Ciampi R, Nikiforov YE. RET/PTC Rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology 2007;148:936-41. [CrossRef]
13. Tang KT, Lee CH. BRAF Mutation in Papillary thyroid carcino- ma: pathogenic role and clinical implications. J Chin Med Assoc 2010;73:113-28. [CrossRef]
14. Greco A, Borrello MG, Miranda C, DeglInnocenti D, Pierotti MA. Molecular pathology of differentiated thyroid cancer. Q J Nucl Med Mol Imaging 2009;53:440-53.
15. Kakudo K, Bai Y, Liu Z, Li Y, Ito Y, Ozaki T. Classification of thyroid follicular cell tumors: with special reference to border- line lesions. Endocr J 2012;59:1-12. [CrossRef]
16. Hunt L J. Molecular testing in solid tumors. Arch Pathol Lab Med 2008;132:164-7.
17. Sheu SY, Schwertheim S, Worm K, Grabellus F, Schmid KW. Diffuse sclerosing variant of papillary thyroid carcinoma: lack of BRAF mutation but occurrence of RET/PTC rearrangements. Mod Pathol 2007;20:779-87. [CrossRef]
18. Fagin JA, Mitsiades N. Molecular pathology of thyroid cancer: diagnostic and clinical implications. Best Pract Res Clin Endo- crinol Metab 2008;22:955-69. [CrossRef]
19. Sadow PM, Heinrich MC, Corless CL, Fletcher JA, Nosé V. Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET/ PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas. En - docr Pathol 2010;21:73-9. [CrossRef]
20. Yip L, Kebebew E, Milas M, Carty SE, Fahey TJ, Parangi S, et al. Summary statement: utility of molecular marker testing in thyroid cancer. Surgery 2010;148:1313-5. [CrossRef]
21. Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and pa- tients age but not with tumor aggressiveness. Virchows Arch 2005;446:589-95. [CrossRef]
22. Lee HJ, Choi J, Hwang TS, Shong YK, Hong SJ, Gong G. De- tection of BRAF mutations in thyroid nodules by allele-specific PCR using a dual priming oligonucleotide system. Am J Clin Pathol 2010;133:802-8. [CrossRef]
23. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Can - cer 2005;12:245-62. [CrossRef]
24. Kumagai A, Namba H, Akanov Z, Saenko VA, Meirmanov S, Ohtsuru A, et al. Clinical implications of pre-operative rapid BRAF analysis for papillary thyroid cancer. Endocr J 2007;54:399-405. [CrossRef]
25. Kim SW, Lee JI, Kim JW, Ki CS, Oh YL, Choi YL, et al. BRAFV600E mutation analysis in fine-needle aspiration cytol- ogy specimens for evaluation of thyroid nodule: A large series in a BRAFV600E-prevalent population. J Clin Endocrinol Metab 2010;95:3693-700. [CrossRef]
26. Marotta V, Guerra A, Sapio MR, Vitale M. RET/PTC rearrange- ment in benign and malignant thyroid diseases: a clinical stand- point. Eur J Endocrinol 2011;165:499-507. [CrossRef]
27. Brzezianska E, Pastuszak-Lewandoska D, Lewinski A. Rear- rangements of NTRK1 oncogene in papillary thyroid carcino- ma. Neuro Endocrinol Lett 2007;28:221-9.
28. Cheung CC, Carydis B, Ezzat S, Bedard YC, Asa SL. Analysis of RET/PTC gene rearrangements refines the fine needle as- piration diagnosis of thyroid cancer. J Clin Endocrinol Metab 2001;86:2187-90. [CrossRef]
29. Marotta V, Guerra A, Sapio MR, Campanile E, Motta M, Fenzi G, et al. Growing thyroid nodules with benign histology and RET rearrangement. Endocr J 2010;57:1081-7. [CrossRef]
30. Chiappetta G, Toti P, Cetta F, Giuliano A, Pentimalli F, Amen- dola I, et al. The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurtle cell adenomas and carcino- mas), but not in oncocytic hyperplastic lesions. J Clin Endocri- nol Metab 2002;87:364-9. [CrossRef]
31. Elisei R, Romei C, Vorontsova T, Cosci B, Veremeychik V, Kuchinskaya E, et al. RET/PTC rearrangements in thyroid nod- ules: studies in irradiated and not irradiated, malignant and be- nign thyroid lesions in children and adults. J Clin Endocrinol Metab 2001;86:3211-6. [CrossRef]
32. Santoro M, Melillo RM, Fusco A. RET/PTC activation in papillary thyroid carcinoma. Eur J Endocrinol 2006;155:645-53. [CrossRef]
33. Cyniak-Magierska A, Wojciechowska-Durczyńska K, Krawc - zyk-Rusiecka K, Zygmunt A, Lewiński A. Assessment of RET/ PTC1 and RET/PTC3 rearrangements in fine-needle aspiration biopsy specimens collected from patients with Hashimotos thy- roiditis. Thyroid Res 2011;4:5. [CrossRef]
34. Basolo F, Giannini R, Monaco C, Melillo RM, Carlomagno F, Pancrazi M, et al. Potent mitogenicity of the RET/PTC3 oncogene correlates with Its prevalence in tall-cell variant of papillary thy- roid carcinoma. Am J Pathol 2002;160:247-54. [CrossRef]
35. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW, Tallini G, et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin En- docrinol Metab 2003;88:2318-26. [CrossRef]
36. Foukakis T, Au AYM, Wallin G, Geli J, Forsberg L, Clifton- Bligh R, et al. The ras effector NORE1A is suppressed in fol- licular thyroid carcinomas with a PAX8-PPARγ fusion. J Clin Endocrinol Metab 2006;91:1143-9. [CrossRef]
37. Marques AR, Espadinha C, Catarino AL, Moniz SN, Pereira T, Sobrinho LG, et al. Expression of PAX8-PPAR rearrangements in both follicular thyroid carcinomas and adenomas; J Clin En- docrinol Metab 2002;87:3947-52. [CrossRef]
38. Nikiforova MN, Kimura ET, Gandhi M, Bindinger PW, Knauf JA, Basolo F, et al. BRAF mutations in thyroid tumors are re- stricted to papillary carcinomas and anaplastic or poorly differ- entiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003;88:5399-404. [CrossRef]
39. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid can- cer: genetic evidence for constitutive activation of the RET/ PTC-RAS-BRAF signaling pathway in papillary thyroid carci- noma. Cancer Res 2003;63:1454-7.
40. Cheung L, Messina M, Gill A, Clarkson A, Learoyd D, Del- bridge L, et al. Detection of the PAX8-PPAR fusion oncogene in both follicular thyroid carcinomas and adenomas. J Clin Endo- crinol Metab 2003;88:354-57. [CrossRef]
41. Trovisco V, Castro V, Soares P, Maximo V, Silva P, Magalhaes J, et al. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol 2004;202:247-51. [CrossRef]
42. Begum S, Rosenbaum E, Henrique R, Cohen Y, Sidransky D, Westra WH. BRAF mutations in anaplastic thyroidcarcinoma: implications for tumor origin, diagnosis and treatment. Mod Pathol 2004;17:1359-63. [CrossRef]
43. Sahin M, Allard BL, Yates M, Powell JG, Wang X, Hay ID et al. PPARγ staining as a surrogate for PAX8/PPARγ fusion on - cogene expression in follicular neoplasms: clinico pathological correlation and histopathological diagnostic value. J Clin Endo- crinol Metab 2005;90:463-8. [CrossRef]
44. Castro P, Rebocho AP, Soares RJ, Magalhaes J, Roque L, Trovis- co V, et al. PAX8-PPAR {gamma} rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab 2006;91:213-20. [CrossRef]
45. Lupi C, Giannini R, Ugolini C, Proietti A, Berti P, Minuto M, et al. Association of BRAF V600E mutation with poor clinicopathologi- cal outcomes in 500 consecutive cases of papillary thyroid carci- noma. J Clin Endocrinol Metab 2007;92:4085-90. [CrossRef]
46. Sapio MR, Guerra A, Posca D, Limone PP, Deandrea M, Motta M, et al. Combined analysis of galectin-3 and BRAFV600E im- proves the accuracy of fine-needle aspiration biopsy with cy- tological findings suspicious for papillary thyroid carcinoma. Endocr Relat Cancer 2007;14:1089-97. [CrossRef]
47. Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 2007;246:466-70. [CrossRef]
48. Mochizuki K, Kondo T, Nakazawa T, Iwashina M, Kawasaki T, Nakamura N, et al. RET rearrangements and BRAF muta- tion in undifferentiated thyroid carcinomas having papillary carcinoma components. Histopathology 2010;57:444-50. [CrossRef]
49. Schimnich AA, Milosevic D, McIver B, Flynn H, Reddi HV, Eb- erhardt NL, et al. Evaluation of the PAX8/PPARG translocation in follicular thyroid cancer with a 4-color reverse-transcription PCR assay and automated high-resolution fragment analysis. Clin Chem 2010;56:391-8. [CrossRef]
50. Guerra A, Sapio MR, Marotta V, Campanile E, Moretti MI, De- andrea M, et al. Prevalence of RET/PTC rearrangement in be- nign and malignant thyroid nodules and its clinical application. Endocr J 2011;58:31-8. [CrossRef]
51. Kurtulmuş N, Düren M, Giray S, İnce Ü, Peker Ö, Aydın Ö, et al. BRAFV600E mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor ag- gressiveness. Endocrine 2012;42:404-10. [CrossRef]
52. Dağlar-Aday A, Toptas B, Ozturk T, Seyhan F, Saygılı N, Eronat AP, et al. Investigation of BRAFV600E mutation in papillary thyroid carcinoma and tumor-surrounding nontumoral tissues. DNA Cell Biol 2013;32:13-8. [CrossRef]
53. Domingues R, Mendonca E, Sobrinho L, Bugalho M.J. Search- ing for RET/PTC rearragements and BRAF V599E mutation in thyroid aspirates might contribute to establish a preopera- tive diagnosis of papillary thyroid carcinoma. Cytopathology 2005;16:27-31. [CrossRef]
54. Romei C, Ciampi R, Faviana P, Agate L, Molinaro E, Bottici V, et al. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. Endocr Relat Cancer 2008;15:511-20. [CrossRef]
55. Xing M. BRAF Mutation in Papillary Thyroid Cancer: Patho- genic role, molecular bases, and clinical implications. Endocr Rev 2007;28:742-62. [CrossRef]
56. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rho- den KJ, et al. BRAF mutation predicts a poorer clinical prog- nosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005;90:6373-9. [CrossRef]
57. Nikiforov YE. Molecular analysis of thyroid tumors. Mod Pathol 2011;24(Suppl 2):S34-43. [CrossRef]
58. Nikiforov YE, Linwah Y, Nikiforova MN. New strategies in di- agnosing cancer in thyroid nodules: impact of molecular mark- ers. Clin Cancer Res 2013;19:2283-8. [CrossRef]